Ironwood Swings to $92M H1 Profit on 74% Revenue Surge, Initiates Pivotal Apraglutide Trial
IRWD has more than doubled off its 52-week low of $0.8.
Summary
Ironwood reported Q2 2026 net income of $51.3M, bringing H1 profit to $92.1M, a sharp reversal from a year-ago loss. Revenue jumped 74% to $219.5M on stronger LINZESS sales. The company initiated a pivotal Phase III trial for apraglutide and disclosed new patent litigation.
Key Events · Earnings and Guidance · IRWD
-
H1 Net Income of $92.1M
Driven by a 74% increase in collaborative revenue to $219.5M, Ironwood swung to a $92.1M profit in H1 2026 from a $13.8M loss in H1 2025.
-
LINZESS U.S. Profit Surge
Collaborative revenue from LINZESS U.S. sales rose to $214.3M in H1 2026 from $124.5M a year ago, reflecting higher net price and prescription demand.
-
Apraglutide Pivotal Trial Initiated
The STARS-2 confirmatory Phase III trial for apraglutide in short bowel syndrome began in June 2026, a key step toward potential FDA approval.
-
Cash Position After Note Repayment
Cash fell to $79.1M at June 30, 2026, from $215.5M at year-end, primarily due to the $200M repayment of convertible notes; the company states it has sufficient liquidity for at least 12 months.
Analysis · IRWD · Life Sciences
A dramatic financial turnaround marks Ironwood's Q2 results: H1 net income reached $92.1 million, compared with a $13.8 million loss a year ago, fueled by a 74% jump in collaborative revenue to $219.5 million. LINZESS U.S. net profits surged on higher net price and prescription demand. The company also initiated the STARS-2 confirmatory Phase III trial for apraglutide, a key pipeline catalyst, and disclosed new ANDA litigation against Alkem. Cash dropped to $79.1 million after repaying $200 million in convertible notes, but the company says existing cash, operating cash flow, and revolver capacity are sufficient for at least 12 months. The results confirm the strong commercial momentum flagged in the recent 8-K guidance raise, but the 10-Q adds granularity on cash runway, pipeline progress, and legal risks.
At the time of this filing, IRWD was trading at $4.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $701.3M. The 52-week trading range was $0.80 to $5.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.